PMC7869746_01
Lipoaspirate collection and ultrasound-guided intrathoracic treatment with MFATPTX. (A) Lipoaspirate collection from the dog's lumbar flanks. (B) Procedure of treatment that was initiated by drainage of abdomen and chest from the exudate fluid followed by the injection of 3 ml of MFAT-PTX intraperitoneally + 2 ml, respectively, into the right and the left pleural spaces. (C) Ultra sound view.
fvets-07-585427-g0001.jpg
PMC7869746_01_fvets-07-585427-g0001.jpg
F1
The procedure is initiated by drainage of the abdomen and chest from the exudate fluid followed by injection of 3 ml of MFAT-PTX intraperitoneally + 2 ml, respectively, into the right and left pleural spaces (Figure 1).
Radiography and computed tomography scan (CT) along the treatment. The figure reports the post-treatment thoracic radiographs (Rx) performed once a month in the first 6 months. They showed progressive reduction of the severe pleural effusion. The computed tomography scan (CT) shows the first CT scan 8 months after first treatment. Transversal view of the soft tissue window, and post-contrast right side effusion. The control 12 months after the first CT scan shows a bilateral pleural effusion mildly increased.
fvets-07-585427-g0002.jpg
PMC7869746_01_fvets-07-585427-g0002.jpg
F2
Post-treatment thoracic radiographs, performed once a month in the first 6 months, showed progressive reduction of the severe pleural effusion (Figure 2). A control CT after 12 months showed only mild difference (Figure 2).
Macroscopic and histological analysis of pleura. (A) The macroscopic analysis shows the presence on the pleural surfaces isles of yellowish fatty material, identified as MFAT-PTX (last administration 2 weeks previously). (B,C) Histological section of pleura (hematoxylin and eosin stain) shows neoplastic cells within the lumen of dilated vessel. Immunohistochemistry for the HBME-mesothelioma marker shows moderate to intense membranous immunolabeling of the tumor cells with apical membrane accentuation.
fvets-07-585427-g0003.jpg
PMC7869746_01_fvets-07-585427-g0003.jpg
F3
Macroscopically all the pleural surfaces presented isles of yellowish fatty material, identified as MFAT-PTX (last administration 2 weeks previously) (Figure 3). Immunohistochemistry for the HBME-mesothelioma marker confirmed the mesothelial origin of the cells (Figure 3).
Plasmatic concentration of paclitaxel (PTX). The figure shows the plasmatic concentration of PTX after the first treatment with MFAT-PTX as reported in the chemotherapeutic protocol. The amount of PTX was checked in the blood after 30 min and 2, 4, and 8 h.
fvets-07-585427-g0004.jpg
PMC7869746_01_fvets-07-585427-g0004.jpg
F4
At 2, 4, and 8 h, the amounts detected in plasma were 28.8, 19.25, and 4.89 ng/ml, respectively (Figure 4).